Bioject Announces Results Of Intradermal Dose Sparing Influenza Study Conducted By The Centers For Disease Control And Prevention
Links shared publicly online about this topic.
- 1,198total visits
Bioject Announces Results Of Intradermal Dose Sparing Influenza Study Conducted By The Centers For Disease Control And Prevention
Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems (NFITS), announced that the Centers for Disease Control and Prevention (CDC) and its co
View full resource at medicalnewstoday.com
Tags: Flu, Disease and Condition, CDC
Most Recently Shared on May 2, 2010 at 12:05 pm By:
Bioject Announces Results Of Intradermal Dose Sparing Influenza Study Conducted By The Centers For Disease Control And... http://mnt.to/3BZM
Also Shared By:
Advertisement
MNT Vaccines
@mnt_vaccines
Bioject Announces Results Of Intradermal Dose Sparing Influenza Study Conducted By The Centers For Disease Control And... http://mnt.to/3BZM
1 year ago...